Key result
Concurrent chronic total occlusion in STEMI patients independently predicted 1-year mortality in both women (HR 3.58; 95% CI 1.69-7.18) and men (HR 2.19; 95% CI 1.20-3.97).
Why the study?
Does the presence of concurrent chronic total occlusion impact 1-year mortality differently in men and women presenting with STEMI?
Cohort (n=2,020)
Does the presence of concurrent chronic total occlusion impact 1-year mortality differently in men and women presenting with STEMI?
Concurrent CTO in STEMI patients is equally prevalent in men and women and serves as a strong independent predictor of 1-year mortality in both sexes, though women experience significantly higher overall mortality.
Answers are grounded in this paper and cite their sources.
Concurrent CTO in STEMI was associated with higher 1-year mortality; leaves open gender-specific prognostic value and management implications.
OBJECTIVES: To determine the prevalence of a concurrent CTO in men and women and to examine its impact on mortality. BACKGROUND: The impact of chronic total occlusion (CTO) in patients with ST-elevation myocardial infarction (STEMI) according to gender has not been assessed. METHODS: Patients referred with STEMI were categorized into single vessel disease (SVD), multivessel disease (MVD) without, with 1 or > 1 CTO. The primary end-point was the 1-year mortality. RESULTS: Among the 2020 STEMI patients included between 2006 and 2011, 24% were female. Women were older, had more hypertension and renal failure (P < 0.0001 for all). The prevalence of 1 or > 1 concurrent CTO was similar in both sexes, 7 and 1%, respectively. Early and late mortality was significantly higher in women compared with men (P < 0.0001). In women, the mortality was significantly worse in patients with > 1 CTO (100%) and with 1 CTO (36.4%) compared with those with MVD without CTO (18.4%) or with SVD (10.4%) (P < 0.0001). MVD with and without concurrent CTO were both independent predictors of 1-year mortality in women (HR 3.58; 95 % CI 1.69-7.18 and HR 2.76; 95 % CI 1.33-5.51) whereas only MVD with CTO was predictive in men (HR 2.19; 95% CI 1.20-3.97). CONCLUSIONS: Among unselected STEMI patients, the prevalence of CTO was equal in both sexes whereas early and late mortality remained significantly higher in women. Other factors than the presence of a concurrent CTO must be explored to explain differences in survival after STEMI between women and men.
No takes yet. Share an insight, caveat, or question.
Bataille et al. (2012) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=2,020). Concurrent chronic total occlusion (CTO) vs. No concurrent CTO (single vessel disease or multivessel disease without CTO) was evaluated on 1-year mortality (HR 3.58, 95% CI 1.69-7.18, p=<0.0001). Concurrent chronic total occlusion in STEMI patients independently predicted 1-year mortality in both women (HR 3.58; 95% CI 1.69-7.18) and men (HR 2.19; 95% CI 1.20-3.97).
Synapse has enriched 10 related papers. Consider them for comparative context: